受强制性开放获取政策约束的文章 - Maria Vidal了解详情
无法在其他位置公开访问的文章：2 篇
A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone receptor–positive HER2-negative breast cancer
A Prat, YH Tsai, T Pascual, L Paré, B Adamo, M Vidal, F Brasó-Maristany, ...
Clinical Cancer Research 26 (23), 6141-6148, 2020
强制性开放获取政策： Breast Cancer Now, UK, European Commission, Government of Spain
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial …
E Ciruelos, M Vidal, E Martínez de Dueñas, N Martínez-Jáñez, ...
Clinical and Translational Oncology 20, 753-760, 2018
强制性开放获取政策： Government of Spain
可在其他位置公开访问的文章：66 篇
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ...
New England Journal of Medicine 387 (1), 9-20, 2022
强制性开放获取政策： US National Institutes of Health
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease
TE Thorgeirsson, F Geller, P Sulem, T Rafnar, A Wiste, KP Magnusson, ...
Nature 452 (7187), 638-642, 2008
强制性开放获取政策： US National Institutes of Health
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types
T Rafnar, P Sulem, SN Stacey, F Geller, J Gudmundsson, A Sigurdsson, ...
Nature genetics 41 (2), 221-227, 2009
强制性开放获取政策： US National Institutes of Health, Cancer Research UK
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ...
NPJ breast cancer 7 (1), 1, 2021
强制性开放获取政策： Breast Cancer Now, UK, European Commission, Government of Spain
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer …
A Llombart-Cussac, J Cortés, L Paré, P Galván, B Bermejo, N Martínez, ...
The lancet oncology 18 (4), 545-554, 2017
强制性开放获取政策： Government of Spain, Susan G. Komen
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
O Martínez-Sáez, N Chic, T Pascual, B Adamo, M Vidal, B González-Farré, ...
Breast cancer research 22, 1-9, 2020
强制性开放获取政策： Breast Cancer Now, UK, European Commission, Government of Spain
Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer
A Prat, LA Carey, B Adamo, M Vidal, J Tabernero, J Cortés, JS Parker, ...
Journal of the National Cancer Institute 106 (8), dju152, 2014
强制性开放获取政策： US National Institutes of Health, Susan G. Komen
Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer
JM Cejalvo, E Martínez de Dueñas, P Galván, S García-Recio, ...
Cancer research 77 (9), 2213-2221, 2017
强制性开放获取政策： US National Institutes of Health, Government of Spain, Susan G. Komen
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
M Castroviejo‐Bermejo, C Cruz, A Llop‐Guevara, S Gutiérrez‐Enríquez, ...
EMBO molecular medicine 10 (12), e9172, 2018
强制性开放获取政策： US National Institutes of Health, Canadian Institutes of Health Research …
Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
A Prat, C Fan, A Fernández, KA Hoadley, R Martinello, M Vidal, M Viladot, ...
BMC medicine 13, 1-11, 2015
强制性开放获取政策： US National Institutes of Health, Government of Spain, Susan G. Komen
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
A Prat, A Lluch, J Albanell, WT Barry, C Fan, JI Chacón, JS Parker, ...
British journal of cancer 111 (8), 1532-1541, 2014
强制性开放获取政策： US National Institutes of Health, Cancer Research UK
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis
F Schettini, T Pascual, B Conte, N Chic, F Brasó-Maristany, P Galván, ...
Cancer treatment reviews 84, 101965, 2020
强制性开放获取政策： US Department of Defense, US National Institutes of Health, Breast Cancer …
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
A Prat, T Pascual, C De Angelis, C Gutierrez, A Llombart-Cussac, T Wang, ...
JNCI: Journal of the National Cancer Institute 112 (1), 46-54, 2020
强制性开放获取政策： US Department of Defense, US National Institutes of Health, Government of …
Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay
A Prat, P Galván, B Jimenez, W Buckingham, HA Jeiranian, C Schaper, ...
Clinical Cancer Research 22 (3), 560-566, 2016
强制性开放获取政策： Susan G. Komen
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual …
P Nuciforo, T Pascual, J Cortés, A Llombart-Cussac, R Fasani, L Paré, ...
Annals of Oncology 29 (1), 170-177, 2018
强制性开放获取政策： Government of Spain, Susan G. Komen
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
F Brasó-Maristany, G Griguolo, T Pascual, L Paré, P Nuciforo, ...
Nature communications 11 (1), 385, 2020
强制性开放获取政策： Breast Cancer Now, UK, Government of Spain
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
L Paré, T Pascual, E Seguí, C Teixidó, M Gonzalez-Cao, P Galván, ...
Annals of Oncology 29 (10), 2121-2128, 2018
强制性开放获取政策： Government of Spain
Symposium review: Decomposing efficiency of milk production and maximizing profit
A Bach, M Terré, M Vidal
Journal of Dairy Science 103 (6), 5709-5725, 2020
强制性开放获取政策： Government of Spain
出版信息和资助信息由计算机程序自动确定